The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: In vitro and in vivo studies

Carcinogenesis

Volumn 34, Issue 4, 2013, Pages 943-951

  Zhou, Dingying ^a   Papayannis, Ioannis ^a   Mackenzie, Gerardo G ^a   Alston, Ninche ^a   Ouyang, Nengtai ^a,b   Huang, Liqun ^a   Nie, Ting ^a   Wong, Chi C ^a   Rigas, Basil ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b Medicon Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MPI 621; PHOSPHO TYROSOL INDOMETHACIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; IC 50; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DINOPROSTONE; FEMALE; HUMANS; INDOMETHACIN; LUNG NEOPLASMS; MICE; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; NF-KAPPA B; ORGANOPHOSPHATES; RATS; RATS, SPRAGUE-DAWLEY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875212454     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs394     Document Type: Article

References (31)

1. Grivennikov, S.I. et al. (2010) Immunity, inflammation, and cancer. Cell, 140, 883-899.
2. Zhang,Z. et al. (2006) NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a chemoprevention target (review). Int. J. Oncol., 29, 185-192.
3. Waddell,W.R. et al. (1980) Indomethacin and ascorbate inhibit desmoid tumors. J. Surg. Oncol., 15, 85-90.
4. Waddell,W.R. et al. (1983) Nonsteroid antiinflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach. J. Surg. Oncol., 22, 197-211.
5. Waddell,W.R. et al. (1983) Sulindac for polyposis of the colon. J. Surg. Oncol., 24, 83-87.
6. Hirata,K. et al. (1994) Regression of rectal polyps by indomethacin suppository in familial adenomatous polyposis. Report of two cases. Dis. Colon Rectum, 37, 943-946.
7. Lundholm,K. et al. (1994) Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res., 54, 5602-5606.
8. Cai,J.B. et al. (2011) A study of 131iodine labeling of indomethacin, its in vivo biological distribution in Lewis-bearing lung cancer, and its induction of apoptosis in lung cancer. Saudi Med. J., 32, 15-22.
9. Kato,T. et al. (2011) Indomethacin induces cellular morphological change and migration via epithelial-mesenchymal transition in A549 human lung cancer cells: a novel cyclooxygenase-inhibition-independent effect. Biochem. Pharmacol., 82, 1781-1791.
10. Brown,J.R. et al. (2004) Cyclooxygenase as a target in lung cancer. Clin. Cancer Res., 10, 4266s-4269s.
11. Ackerstaff,E. et al. (2007) Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line. Neoplasia, 9, 222-235.
12. Henry,D. et al. (1996) Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ, 312, 1563-1566.
13. Seideman,P. et al. (1991) Cerebral blood flow and indomethacin drug levels in subjects with and without central nervous side effects. Br. J. Clin. Pharmacol., 31, 429-432.
14. Huang,L. et al. (2011) The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats. Br. J. Pharmacol., 162, 1521-1533.
15. Huang,L. et al. (2011) Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds. Cancer Res., 71, 7617-7627.
16. Huang,L. et al. (2010) Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect. Carcinogenesis, 31, 1982-1990.
17. Mackenzie,G.G. et al. (2010) Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice. Gastroenterology, 139, 1320-1332.
18. Sun,Y. et al. (2012) Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system. Breast Cancer Res., 14, R20.
19. Piazza,G.A. et al. (2009) A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev. Res. (Phila.), 2, 572-580.
20. Xie,G. et al. (2011) Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. J. Pharmacol. Exp. Ther., 337, 876-886.
21. Mackenzie,G.G. et al. (2011) Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice. Cancer Prev. Res. (Phila.), 4, 1052-1060.
22. Whiteley,P.E. et al. (2001) Models of inflammation: measuring gastrointestinal ulceration in the rat. Curr. Protoc. Pharmacol., Chapter 10, Unit 10.2.
23. Xie,M. et al. (2002) Human and rodent carboxylesterases: immunorelatedness, overlapping substrate specificity, differential sensitivity to serine enzyme inhibitors, and tumor-related expression. Drug Metab. Dispos., 30, 541-547.
24. Wong,C.C. et al. (2012) Carboxylesterases 1 and 2 hydrolyze phospho-NSAIDs drugs: relevance to their pharmacological activity. J. Pharmacol. Exp. Ther., 340(2), 422-432.
25. Covas,M.I. et al. (2003) Bioavailability of tyrosol, an antioxidant phenolic compound present in wine and olive oil, in humans. Drugs Exp. Clin. Res., 29, 203-206.
26. Wong,C.C. et al. (2012) Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents. J. Pharmacol. Exp. Ther., 341, 572-578.
27. Krysan,K. et al. (2006) The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med. Chem., 6, 209-220.
28. Horn,L. et al. (2009) Targeting the eicosanoid pathway in non-small-cell lung cancer. Expert Opin. Ther. Targets, 13, 675-688.
29. Shiff,S.J. et al. (1999) The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs) [comment]. J. Exp. Med., 190, 445-450.
30. Warner,T.D. et al. (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl Acad. Sci. U.S.A., 96, 7563-7568.
31. Ganchi,P.A. et al. (1992) I kappa B/MAD-3 masks the nuclear localization signal of NF-kappa B p65 and requires the transactivation domain to inhibit NF-kappa B p65 DNA binding. Mol. Biol. Cell, 3, 1339-1352.